Clinical Trial

PETRA: Pictorial Assessment of Task Occurrence and Upper Limb Avoidance Behaviors

Study acronym: PETRA
Recruiting
View on ClinicalTrials.gov →
Summary
The clinical evaluation of patients suspected of having thoracic brachial outlet syndrome (TBS) is not standardized, as it may be for the lower limbs. Assessment of symptoms and functional impact is based on questionnaires (Disability of the Arm, Shoulder and Hand: DASH, Short Form 36: SF36, Mobility of the Arm and Shoulder: MASC, Thoracic and Upper limb ischemia Pain: TULIP), which are complex to complete, sometimes non-lateralized, and do not take into account the frequency of occurrence of certain gestures or the avoidance behaviours adopted by patients. For avoidance behaviors, a recent tool has been proposed in the form of the Avoidance Daily Activities Photo Scale (ADAP shoulder scale). However, this questionnaire has not been translated into French and does not reflect the frequency with which patients are confronted with the different tasks proposed. The aim of this study is to test the feasibility of a new questionnaire (PETRA), derived from the ADAP-shoulder scale, which is simple for patients to complete, quick to analyze and calculable directly by the doctor, and suitable for the general population, whether for initial assessment or follow-up. The PETRA aims to assess avoidance behaviours in the face of daily tasks, but also the frequency of occurrence of these tasks in order to evaluate a disabling score that weights the avoidance index according to the degree of exposure to the proposed tasks. The investigators hypothesize that the PETRA questionnaire could eventually be used routinely.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-07-01 -> 2027-06 2026-06-17
minor Completion moved earlier: 2027-07-01 -> 2027-06 2026-06-17
Trial Details
NCT Number NCT07031791
Lead Sponsor University Hospital, Angers
Conditions Thoraco-brachial Outlet Syndrome, ADAP-shoulder Scale, PETRA
Enrollment 200 participants
Start Date 2025-06-27
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-16